Pruritus Treatment Guidelines

Introduction to Pruritus Treatment

Sertraline is the most effective SSRI for treating pruritus, particularly in cholestatic and uremic itch, and should be considered as a third-line treatment option after first-line cholestyramine and second-line rifampicin, as recommended by the British Journal of Dermatology and Gut guidelines 1, 2

For cholestatic pruritus, cholestyramine (4-16 g/day) is recommended as a first-line treatment, according to the Gut guideline 2
For polycythemia vera-associated pruritus, aspirin 300 mg daily is recommended as a first-line treatment, as suggested by the British Journal of Dermatology guideline 1

For cholestatic pruritus, rifampicin (300-600 mg/day) is recommended as a second-line treatment, according to the Gut guideline 2
For polycythemia vera-associated pruritus, interferon-alpha and UVB phototherapy are recommended as second-line treatments, as suggested by the British Journal of Dermatology guideline 1

Sertraline (75-100 mg daily) is recommended as a third-line treatment for cholestatic pruritus, according to the Gut guideline 2
Paroxetine or fluvoxamine are recommended for neuropathic pruritus, and mirtazapine is recommended for generalized pruritus of unknown origin, as suggested by the British Journal of Dermatology guideline 1

Sertraline should be started at 25-50 mg daily and titrated up to 75-100 mg daily as needed and tolerated 1, 2
Paroxetine is typically given at 20 mg daily, and fluvoxamine is started at 50 mg daily and can be increased to 100 mg daily 1

Elderly patients may be more sensitive to SSRI side effects and should start at lower doses, as recommended by the British Journal of Dermatology guideline 1
Patients with hepatic impairment should use sertraline with caution, and those with renal impairment should be monitored closely, according to the Gut guideline 2
Pregnancy requires a risk-benefit assessment, and pediatric use of sertraline has been successful in children with cholestatic pruritus at 1-4 mg/kg/day, although this is not explicitly cited, similar dosing is mentioned in the context of 1, 2

An initial trial of 4-8 weeks is recommended to assess efficacy, and treatment may be continued long-term as needed, with periodic attempts at dose reduction or discontinuation, as suggested by the British Journal of Dermatology and Gut guidelines 1, 2